
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.
We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.
argenx is a global immunology company developing therapies for individuals living with autoimmune diseases. argenx is building a world-class portfolio of biologics in both early and late stages of development. VYVGART® / VYVGART Hytrulo® (efgartigimod) is approved for generalized Myasthenia Gravis (gMG) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and is being evaluated for several additional indications, including three rheumatology indications: autoimmune myositis, Sjögren's disease, and systemic sclerosis.
The Director, US HCP Marketing will lead the development and execution of the US HCP marketing strategy for Sjögren's disease, with near-term ownership of market development and disease state education to increase understanding of the disease, its burden, and unmet need among priority HCP audiences. This role will shape the commercial strategy and build the foundation required for launch readiness.
This role will report to the Senior Director of US HCP Marketing, Rheumatology Lead, and will serve as the HCP marketing lead for Sjögren's disease. The Director will partner closely with internal cross-functional leaders and external agencies to define and deliver integrated personal and non-personal engagement across field, digital, media, peer-to-peer, and national and regional congress channels. In close collaboration with the broader HCP Community, this role will own the US unbranded strategy and contribute meaningfully to VYVGART Hytrulo brand strategy, indication planning, and launch readiness.
This is an exciting opportunity to join an innovative, growing team and shape a new market development program from the ground up. We seek a strategic, hands-on commercial leader who thrives in a nimble, fast-paced environment, is passionate about science, and is deeply motivated by delivering value to people living with rare diseases.
#LI-hybrid
This job is eligible to participate in our short-term and long-term incentive programs, subject to the terms and conditions of those plans and applicable policies. It also includes a comprehensive benefits package, including but not limited to retirement savings plans, health benefits and other benefits subject to the terms of the applicable plans and program guidelines.
At argenx, all applicants are welcomed in an inclusive environment. They will receive equal consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other applicable legally protected characteristics. argenx is proud to be an equal opportunity employer.
Before you submit your application, CV or any other personal details to us, please review our argenx Privacy Notice for Job Applicants to learn more about how argenx B.V. and its affiliates (“argenx”) will handle and protect your personal data. If you have any questions or you wish to exercise your privacy rights, please contact our Global Privacy Office by email at privacy@argenx.com.
If you require reasonable accommodation in completing your application, interviewing, or otherwise participating in the candidate selection process please contact us at hr.us@argenx.com. Only inquiries related to an accommodation request will receive a response.

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.